Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Rittmeyer

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Immunotherapy|May 24, 2019
Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancerAnnett Schiwitza, Hans-Ulrich Schildhaus, Birgit Zwerger, et al.
Oncotargets and Therapy|March 7, 2017
Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trialSylvia Guetz, Amanda Tufman, Joachim von Pawel, et al.
The European Respiratory Journal|August 26, 2017
Treatment of limited disease small cell lung cancer: the multidisciplinary teamMarkus Glatzer, Achim Rittmeyer, Joachim Müller, et al.
Clinical Pharmacology and Therapeutics|September 11, 2023
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World DataShivani K Mhatre, Robson J M Machado, Thanh G N Ton, et al.
Deutsche Medizinische Wochenschrift (1946)|February 25, 2017
[Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study]David Felix Heigener, Gert Hoeffken, Dieter Wuerflein, et al.
Journal for Immunotherapy of Cancer|March 19, 2021
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxelDavid Gandara, Martin Reck, Denis Moro-Sibilot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2013
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089)Achim Rittmeyer, Vera Gorbunova, Anders Vikström, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical TrialsJulien Mazieres, Achim Rittmeyer, Shirish Gadgeel, et al.
Clinical Lung Cancer|July 19, 2018
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung CancerRodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Reply to B.M. StrebelFabrice Barlesi, Arnaud Scherpereel, Achim Rittmeyer, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Immunotherapy|May 24, 2019
Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancerAnnett Schiwitza, Hans-Ulrich Schildhaus, Birgit Zwerger, et al.
Oncotargets and Therapy|March 7, 2017
Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trialSylvia Guetz, Amanda Tufman, Joachim von Pawel, et al.
The European Respiratory Journal|August 26, 2017
Treatment of limited disease small cell lung cancer: the multidisciplinary teamMarkus Glatzer, Achim Rittmeyer, Joachim Müller, et al.
Clinical Pharmacology and Therapeutics|September 11, 2023
Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World DataShivani K Mhatre, Robson J M Machado, Thanh G N Ton, et al.
Deutsche Medizinische Wochenschrift (1946)|February 25, 2017
[Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study]David Felix Heigener, Gert Hoeffken, Dieter Wuerflein, et al.
Journal for Immunotherapy of Cancer|March 19, 2021
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxelDavid Gandara, Martin Reck, Denis Moro-Sibilot, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2013
Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089)Achim Rittmeyer, Vera Gorbunova, Anders Vikström, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical TrialsJulien Mazieres, Achim Rittmeyer, Shirish Gadgeel, et al.
Clinical Lung Cancer|July 19, 2018
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung CancerRodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Reply to B.M. StrebelFabrice Barlesi, Arnaud Scherpereel, Achim Rittmeyer, et al.
Pageof 6